All In MedTech

Device Trial Radar · NCT02402374

Evaluate the Safety and Efficacy of RegenKit Autologous PRP Gel for the Treatment of Diabetic Foot Ulcer

Randomized, Placebo-controlled, Blind-assessor Study to Evaluate the Safety and Efficacy of Autologous Platelet Rich Plasma Gel Prepared With the RegenKit-BCT Plus Family of Kits for the Treatment of Diabetic Foot Ulcer

Last checked: Nov 20, 2026Latest source record: Oct 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

192

Planned (sponsor's estimate)

Start

Apr 12, 2018

Primary completion

Oct 30, 2020

Study completion Dec 30, 2020

Sponsor

Lead sponsor
Regen Lab SANot on our public-company list
Sponsor type
Industry
Collaborators
RegenLab USA LLC
First posted
Mar 30, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Autologous platelet-rich plasma (PRP) gel was reported to have very good outcomes in the treatment of foot ulcers in pilot studies and retrospective uncontrolled trials. Therefore, a larger randomized, placebo-controlled clinical trial will be useful to determine whether platelet-rich plasma is safe and effective for the treatment of diabetic foot ulcers (DFU).

Conditions

  • Diabetic Foot Ulcers

Interventions

  • Autologous platelet rich plasma gelDevice

    PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds

  • PlaceboDevice

    Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with complete wound closureTime frame: 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Futuro Clinical Trials

    McAllen, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.